WO2001035096A3 - Diseases associated with altered mitochondrial function - Google Patents

Diseases associated with altered mitochondrial function Download PDF

Info

Publication number
WO2001035096A3
WO2001035096A3 PCT/US2000/031119 US0031119W WO0135096A3 WO 2001035096 A3 WO2001035096 A3 WO 2001035096A3 US 0031119 W US0031119 W US 0031119W WO 0135096 A3 WO0135096 A3 WO 0135096A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
diseases associated
mitochondrial
biogenesis
mitochondrial function
Prior art date
Application number
PCT/US2000/031119
Other languages
French (fr)
Other versions
WO2001035096A2 (en
Inventor
Christen M Anderson
William Clevenger
David K Becker
Kathryn A Grako
Original Assignee
Mitokor
Christen M Anderson
William Clevenger
David K Becker
Kathryn A Grako
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor, Christen M Anderson, William Clevenger, David K Becker, Kathryn A Grako filed Critical Mitokor
Priority to AU17632/01A priority Critical patent/AU1763201A/en
Publication of WO2001035096A2 publication Critical patent/WO2001035096A2/en
Publication of WO2001035096A3 publication Critical patent/WO2001035096A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Abstract

Compositions and methods are provided for the treatment of diseases associated with altered mitochondrial function, and in particular, for type 2 diabetes mellitus. Administration of an agent that increases mitochondrial mass, including promotion of mitochondrial biogenesis by induction of a PGC gene e.g., PGC-1), a UCP gene and/or a nuclear regulatory factor gene e.g., NRF-1), is also disclosed. Screening assays for agents that regulate such genes involved in mitochondiral biogenesis, and for genes and gene products that are regulated by such genes involved in mitochondrial biogenesis, are also provided.
PCT/US2000/031119 1999-11-10 2000-11-13 Diseases associated with altered mitochondrial function WO2001035096A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17632/01A AU1763201A (en) 1999-11-10 2000-11-13 Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16453399P 1999-11-10 1999-11-10
US60/164,533 1999-11-10

Publications (2)

Publication Number Publication Date
WO2001035096A2 WO2001035096A2 (en) 2001-05-17
WO2001035096A3 true WO2001035096A3 (en) 2001-11-29

Family

ID=22594937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031119 WO2001035096A2 (en) 1999-11-10 2000-11-13 Diseases associated with altered mitochondrial function

Country Status (2)

Country Link
AU (1) AU1763201A (en)
WO (1) WO2001035096A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118873B2 (en) 2000-12-12 2006-10-10 The University Of Connecticut Polynucleotides encoding cellular transporters and methods of use thereof
CA2416332C (en) * 2001-05-29 2012-11-13 The University Of British Columbia Pharmacological applications of mitochondrial dna assays
EP1264841A1 (en) * 2001-06-08 2002-12-11 Novo Nordisk A/S DNA encoding a mutant peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1), detection methods and test kits therefor
AU2002311013A1 (en) * 2001-06-08 2002-12-23 Novo Nordisk A/S Dna encoding a mutant peroxisome proliferator-activated receptor gamma coactivator-1 (pgc-1), detection methods and test kits therefor
ATE480620T1 (en) * 2001-07-05 2010-09-15 Dana Farber Cancer Inst Inc NEW PGC-1 ISOFORMS AND THEIR USES
AU2003260618A1 (en) * 2002-06-24 2004-01-06 Exonhit Therapeutics Sa Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
WO2005003766A2 (en) * 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
EP2544692A4 (en) * 2010-03-10 2013-08-07 Univ Health Network Use of tigecycline for treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein
WO1998054220A1 (en) * 1997-05-30 1998-12-03 Dana-Farber Cancer Institute PGC-1, A NOVEL BROWN FAT PPARη COACTIVATOR
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO1999007358A1 (en) * 1997-08-05 1999-02-18 Consejo Superior Investigaciones Cientificas Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein
WO1998054220A1 (en) * 1997-05-30 1998-12-03 Dana-Farber Cancer Institute PGC-1, A NOVEL BROWN FAT PPARη COACTIVATOR
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO1999007358A1 (en) * 1997-08-05 1999-02-18 Consejo Superior Investigaciones Cientificas Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2
EP1018338A1 (en) * 1997-08-05 2000-07-12 Consejo Superior De Investigaciones Cientificas Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUGNEJA SAJIV ET AL: "Serine phosphorylation within a concise amino-terminal domain in nuclear respiratory factor 1 enhances DNA binding.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 30, 1997, pages 18732 - 18739, XP002169687, ISSN: 0021-9258 *
PUIGSERVER P ET AL: "COLD-INDUCIBLE COACTIVATOR OF NUCLEAR RECEPTORS LINKED TO ADAPTIVE THERMOGENESIS", CELL,CELL PRESS, CAMBRIDGE, NA,US, vol. 92, 20 March 1998 (1998-03-20), pages 829 - 839, XP000919368, ISSN: 0092-8674 *
WU ZHIDAN ET AL: "Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1.", CELL, vol. 98, no. 1, 9 July 1999 (1999-07-09), pages 115 - 124, XP002169686, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2001035096A2 (en) 2001-05-17
AU1763201A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
OA09458A (en) Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
AU4742193A (en) Cyclohex(en)ylcarboxamides, the preparation thereof, and compositions containing them for controlling fungal pests
NO973923L (en) New taxoids, their preparation as well as pharmaceutical preparations containing the compounds
FI973828A0 (en) Compounds and compositions for administering the active ingredients
ATE494009T1 (en) PRODRUGS, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS
DE68910853T2 (en) Triazole derivatives, their preparation and their use as fungicides.
AU7565694A (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
AU3575193A (en) S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
HUP9900881A3 (en) 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them
AU4770596A (en) Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products
GR3031711T3 (en) Cephalosporins and homologues, preparations and pharmaceutical compositions.
DE69815094D1 (en) 2- (IMINOETHYL) -AMINOPHENYL DERIVATIVES, THEIR PRODUCTION, THE USE THEREOF AS MEDICAMENTS AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
HK1032958A1 (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments.
NO305903B1 (en) Benzonitriles and benzofluorides, drugs comprising the compounds, pharmaceutical compositions containing the compounds, and use of the compounds for the preparation of pharmaceutical preparations
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
WO2001035096A3 (en) Diseases associated with altered mitochondrial function
AU5339594A (en) Novel taxane derivatives, their preparation and pharmaceutical compositions containing them
BR9811582B1 (en) compounds derived from 4-oxo-3,5-dihydro-4h-pyridazine [4,5-b] indole-1-acetamide, medicament and pharmaceutical composition containing them.
AU4246489A (en) New benzoxazolinone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3781627D1 (en) INDANDERIVATES, METHODS FOR THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE INTERIM PRODUCTS OBTAINED.
DE69407057D1 (en) 1,3.5 (10) - ESTRATRIA DERIVATIVES WITH ORAL EFFECT
FI942222A (en) Process for the preparation of dry-treated particles, so obtained dry-treated particles and pharmaceutical compositions containing them
DK0588177T3 (en) Interferon-alpha / beta-binding protein, preparation thereof and pharmaceutical preparations containing the protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP